[Ip-health] IPAB hearing on the Nexavar compulsory license, part 1, R&D costs | Knowledge Ecology International

Jamie Love james.love at keionline.org
Sun Jan 20 00:00:39 PST 2013

In this blog, I drill down into one of the major issues in the trials, the
issue of Bayer's R&D costs for Nexavar.


More information about the Ip-health mailing list